Serum and urine markers of collagen degradation reflect renal fibrosis in experimental kidney diseases

Nephrology Dialysis Transplantation

Volumn 30, Issue 7, 2015, Pages 1112-1121

  Papasotiriou, Marios ^a,b   Genovese, Federica ^c   Klinkhammer, Barbara M ^a   Kunter, Uta ^a   Nielsen, Signe H ^c   Karsdal, Morten A ^c   Floege, Jürgen ^a   Boor, Peter ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

biomarkers; interstitial fibrosis; rat models

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BIOLOGICAL MARKER; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CREATININE; METALLOPROTEINASE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL KIDNEY DISEASE; KIDNEY FIBROSIS; MALE; NEPHRECTOMY; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN URINE LEVEL; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RAT; ADVERSE EFFECTS; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; ENZYME IMMUNOASSAY; FIBROSIS; FISCHER 344 RAT; KIDNEY DISEASES; URINE;

ANIMALS; BIOMARKERS; COLLAGEN TYPE I; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSIS; IMMUNOENZYME TECHNIQUES; KIDNEY DISEASES; MALE; NEPHRECTOMY; RATS; RATS, INBRED F344;

EID: 84936741712     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv063     Document Type: Article

References (38)

1. Yanagita M. Inhibitors/antagonists of TGF-beta system in kidney fibrosis. Nephrol Dial Transplant 2012; 27: 3686-3691
2. Floege J, Johnson RJ, Feehally J (eds). Comprehensive Clinical Nephrology. 4th edn. St. Louis, MO: Saunders/Elsevier, 2010
3. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010; 6: 643-656
4. Miyata T, Ando T, Hiragi H et al. Drug discovery in renal disease-towards a more efficient framework. Nat Rev Nephrol 2014; 10: 290-296
5. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007; 381: 107-113
6. Genovese F, Manresa AA, Leeming DJ et al. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair 2014; 7: 4
7. Zhen EY, Brittain IJ, Laska DA et al. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 2008; 58: 2420-2431
8. Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol 2012; 302: F1351-F1361
9. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007; 292: F905-F911
10. Karsdal MA, Delvin E, Christiansen C. Protein fingerprints-relying on and understanding the information of serological protein measurements. Clin Biochem 2011; 44: 1278-1279
11. Barascuk N, Veidal SS, Larsen L et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neoepitope of type III collagen. Clin Biochem 2010; 43: 899-904
12. Leeming D, He Y, Veidal S et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 2011; 16: 616-628
13. Klinkhammer BM, Kramann R, Mallau M et al. Mesenchymal stem cells from rats with chronic kidney disease exhibit premature senescence and loss of regenerative potential. PLoS ONE 2014; 9: e92115
14. Boor P, Celec P, Martin IV et al. The peroxisome proliferator-activated receptor-alpha agonist, BAY PP1, attenuates renal fibrosis in rats. Kidney Int 2011; 80: 1182-1197
15. Ostendorf T, Rong S, Boor P et al. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17: 1054-1062
16. Boor P, Konieczny A, Villa L et al. PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol Dial Transplant 2007; 22: 1323-1331
17. Neven E, D'Haese PC. Vascular calcification in chronic renal failure: what have we learned from animal studies? Circ Res 2011; 108: 249-264
18. Eitner F, Ostendorf T, Van Roeyen C et al. Expression of a novel PDGF isoform, PDGF-C, in normal and diseased rat kidney. J Am Soc Nephrol 2002; 13: 910-917
19. Nielsen MJ, Nedergaard AF, Sun S et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res 2013; 5: 303-315
20. Jefferson JA, Johnson RJ. Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1. 1 model). J Nephrol 1999; 12: 297-307
21. de Mik SM, Hoogduijn MJ, de Bruin RW et al. Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models. BMC Nephrol 2013; 14: 74
22. Yokozawa T, Zheng PD, Oura H et al. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986; 44: 230-234
23. Ghoul BE, Squalli T, Servais A et al. Urinary procollagen III aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist. Clin J Am Soc Nephrol 2010; 5: 205-210
24. Teppo AM, Tornroth T, Honkanen E et al. Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients. Transplantation 2003; 75: 2113-2119
25. Dellegrottaglie S, Sands RL, Gillespie BW et al. Association between markers of collagen turnover, arterial stiffness and left ventricular hypertrophy in chronic kidney disease (CKD): the Renal Research Institute (RRI)-CKD study. Nephrol Dial Transplant 2011; 26: 2891-2898
26. Araki S, Haneda M, Koya D et al. Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes Care 2010; 33: 1805-1810
27. Okonogi H, Nishimura M, Utsunomiya Y et al. Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol 2001; 55: 357-364
28. Ronco P, Chatziantoniou C. Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives. Kidney Int 2008; 74: 873-878
29. Karsdal MA, Henriksen K, Leeming DJ et al. Novel combinations of posttranslational modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease? Clin Biochem 2010; 43: 793-804
30. Veidal SS, Vassiliadis E, Barascuk N et al. Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int 2010; 30: 1293-1304
31. Schierwagen R, Leeming DJ, Klein S et al. Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. Front Physiol 2013; 4: 195
32. Vassiliadis E, Larsen DV, Clausen RE et al. Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type III, in a rat model of reversible carbon-tetrachlorideinduced fibrosis. Biomark Insights 2011; 6: 49-58
33. Leeming DJ, Karsdal MA, Byrjalsen I et al. Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther 2013; 38: 1086-1096
34. Willumsen N, Bager CL, Leeming DJ et al. Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls. BMC Cancer 2013; 13: 554
35. Leeming DJ, Sand JM, Nielsen MJ et al. Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Biomark Insights 2012; 7: 119-126
36. Vassiliadis E, Veidal SS, Kristiansen MN et al. Peptidyl arginine deiminase inhibitor effect on hepatic fibrogenesis in a CCl4 pre-clinical model of liver fibrosis. Am J Transl Res 2013; 5: 465-469
37. Zurbig P, Jerums G, Hovind P et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012; 61: 3304-3313
38. Good DM, Zurbig P, Argiles A et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010; 9: 2424-2437